Ultragenyx Pharmaceutical Inc
For the period ended Dec 31, 2024. Filed Feb 19, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 19, 2025
RARE$16.41+6.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
During the three months ended December 31, 2024, the following directors and officers adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Name and Title | Date Adopted | Aggregate Number of Shares of Common Stock to be Sold (Subject to Certain Conditions) | Plan End Date |
|---|---|---|---|
| Shehnaaz Suliman, M.D., Ph.D.Board Member | November 8, 2024 | Up to 27,110 shares, all of which are shares to be acquired upon the exercise of stock options | November 7, 2025 |
| Corsee Sanders, Ph.D.,Board Member | November 15, 2024 | Up to 2,405 shares | June 26, 2025 |
| Matthew Fust, Board Member | November 22, 2024 | Up to 15,000 shares, all of which are shares to be acquired upon the exercise of stock options | November 21, 2025 |
| Eric Crombez, M.D.EVP, Chief Medical Officer | December 3, 2024 | Up to 64,235 shares, 28,500 of which are shares to be acquired upon the exercise of stock options | December 3, 2025 |
| Howard Horn,EVP, Chief Financial Officer | December 9, 2024 | Up to 17,477 shares | December 9, 2025 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.